Merck KGaA Bags Exclusive Rights To Develop, Sell Debiopharm’s Xevinapant

The IAP antagonist Is In Phase III Trials For Head And Neck Cancer

 
• By Sten Stovall
  
Brain Scan
Merck will use its expertise in head and neck cancer to advance xevinapant. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip